title: Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
abstract: BACKGROUND
  Cisplatin is widely used in combination chemotherapy against a variety of tumors; however, the optimal administration schedule of cisplatin is still controversial. To clarify the pharmacokinetic differences according to the administration schedules of cisplatin, we compared three different administration schedules of cisplatin such as single short-term infusion, daily short-term infusion and daily continuous infusion in combination with 5-fluorouracil. Preliminary clinical responses and toxicities were also investigated.
  
  
  METHODS
  A total of 12 courses in combination of cisplatin and 5-fluorouracil therapy was studied. The schedules of cisplatin tested were as follows: single short-term infusion (80 mg/m2, day 1,2 h div., n = 4), daily short-term infusion (20 mg/m2, days 1 to 5, 2 h div., n = 4), daily continuous infusion (100 mg/m2, 120 h, n = 4). In all schedules, 5-fluorouracil was continuously administered at a dose of 800 mg/m2/day on days 1 to 5. The area under the time-concentration curve (AUC) and the maximum concentration (Cmax) of total and free Pt were investigated.
  
  
  RESULTS
  The highest AUC of total and free Pt and the lowest Cmax of free Pt were observed in the daily continuous infusion (total AUC; 162.53 +/- 18.39 micrograms h/ml, free AUC; 5.50 +/- 0.9 micrograms h/ml, free Cmax; 0.07 +/- 0.01 microgram/ml, mean +/- SEM). Two patients in the single short-term infusion and one patient in the daily continuous infusion indicated partial responses clinically. No nephrotoxicity or ototoxicity was observed. All toxicities were mild and tolerable in all regimens; however, the incidence of GI toxicity in daily continuous infusion seemed to be relatively higher.
  
  
  CONCLUSIONS
  Daily continuous infusion of cisplatin gave the best pharmacokinetic results and to evaluate the clinical advantage of this schedule a prospective randomized trial should be conducted with sufficient numbers of patients.
authors.affiliation: Department of Surgery 1, Iwate Medical University, Morioka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: M
authors.initials: M
authors.lastname: Terashima
authors.forename: H
authors.initials: H
authors.lastname: Kawamura
authors.forename: I
authors.initials: I
authors.lastname: Takiyama
authors.forename: K
authors.initials: K
authors.lastname: Koeda
authors.forename: A
authors.initials: A
authors.lastname: Takagane
authors.forename: N
authors.initials: N
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Ishida
authors.forename: T
authors.initials: T
authors.lastname: Iwaya
authors.forename: C
authors.initials: C
authors.lastname: Maesawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshinari
authors.forename: K
authors.initials: K
authors.lastname: Saito
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000097:blood; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D010984:Platinum; D002945:Cisplatin; D005472:Fluorouracil